Fragment-Based Discovery of Bromodomain Inhibitors Part 2: Optimization of Phenylisoxazole Sulfonamides
Authors:
- 11 January 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (2) , 587-596
Abstract
Bromodomains are epigenetic reader modules that regulate gene transcription through their recognition of acetyl-lysine modified histone tails. Inhibitors of this protein–protein interaction have the potential to modulate multiple diseases as demonstrated by the profound anti-inflammatory and antiproliferative effects of a recently disclosed class of BET compounds. While these compounds were discovered using phenotypic assays, here we present a highly efficient alternative approach to find new chemical templates, exploiting the abundant structural knowledge that exists for this target class. A phenyl dimethyl isoxazole chemotype resulting from a focused fragment screen has been rapidly optimized through structure-based design, leading to a sulfonamide series showing anti-inflammatory activity in cellular assays. This proof-of-principle experiment demonstrates the tractability of the BET family and bromodomain target class to fragment-based hit discovery and structure-based lead optimization.Keywords
This publication has 15 references indexed in Scilit:
- Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead DiscoveryJournal of Medicinal Chemistry, 2012
- Discovery and Characterization of Small Molecule Inhibitors of the BET Family BromodomainsJournal of Medicinal Chemistry, 2011
- Discovery of Modulators of Protein-Protein Interactions: Current Approaches and LimitationsCurrent Topics in Medicinal Chemistry, 2011
- Suppression of inflammation by a synthetic histone mimicNature, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- An emerging role for bromodomain‐containing proteins in chromatin regulation and transcriptional control of adipogenesisFEBS Letters, 2010
- Recent progress in fragment-based lead discoveryCurrent Opinion in Pharmacology, 2009
- Small molecular weight protein–protein interaction antagonists—an insurmountable challenge?Current Opinion in Chemical Biology, 2008
- Reaching for high-hanging fruit in drug discovery at protein–protein interfacesNature, 2007
- Ligand efficiency: a useful metric for lead selectionDrug Discovery Today, 2004